Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.

[1]  G. Mårtensson,et al.  Cytomegalovirus and long-term outcome after lung transplantation in Gothenburg, Sweden , 2010, Scandinavian journal of infectious diseases.

[2]  D. Snydman,et al.  Cytomegalovirus in Solid Organ Transplant Recipients , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  J. Stoner,et al.  Valganciclovir for Cytomegalovirus Prevention in Solid Organ Transplant Patients: An Evidence-Based Reassessment of Safety and Efficacy , 2009, PloS one.

[4]  A. Pastor,et al.  A Multicenter Study of Valganciclovir Prophylaxis up to Day 120 in CMV‐Seropositive Lung Transplant Recipients , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  T. Buclin,et al.  Population Pharmacokinetics of Ganciclovir in Solid-Organ Transplant Recipients Receiving Oral Valganciclovir , 2009, Antimicrobial Agents and Chemotherapy.

[6]  O. Manuel,et al.  Lack of Association Between ß-herpesvirus Infection and Bronchiolitis Obliterans Syndrome in Lung Transplant Recipients in the Era of Antiviral Prophylaxis , 2009, Transplantation.

[7]  G. Lang,et al.  Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[8]  R. Speich,et al.  Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  David E. Taylor,et al.  Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[10]  A. Zaas,et al.  A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[11]  W. Kremers,et al.  Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[12]  A. Limaye,et al.  Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  A. Cochrane.  Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients. , 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[14]  H. Ulmer,et al.  Combined CMV Prophylaxis Improves Outcome and Reduces the Risk for Bronchiolitis Obliterans Syndrome (BOS) after Lung Transplantation , 2006, Transplantation.

[15]  F. Morell,et al.  Preemptive therapy with intravenous ganciclovir for the prevention of cytomegalovirus disease in lung transplant recipients. , 2005, Transplantation proceedings.

[16]  B. Alexander,et al.  Pharmacodynamics of Oral Ganciclovir and Valganciclovir in Solid Organ Transplant Recipients , 2005, Transplantation.

[17]  Barbara Alexander,et al.  Pharmacokinetic Profile of Ganciclovir After its Oral Administration and From its Prodrug, Valganciclovir, in Solid Organ Transplant Recipients , 2005, Clinical pharmacokinetics.

[18]  J. Preiksaitis,et al.  A Trial of Valganciclovir Prophylaxis for Cytomegalovirus Prevention in Lung Transplant Recipients , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  S. Gruber,et al.  Cytomegalovirus prophylaxis with valganciclovir in African–American renal allograft recipients based on donor/recipient serostatus , 2005, Clinical transplantation.

[20]  M. Tamm,et al.  Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. , 2004, American journal of respiratory and critical care medicine.

[21]  M. Zamora,et al.  Following Universal Prophylaxis with Intravenous Ganciclovir and Cytomegalovirus Immune Globulin, Valganciclovir is Safe and Effective for Prevention of CMV Infection Following Lung Transplantation , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  S. Baroletti,et al.  Efficacy and Safety of Low‐Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Renal Transplant Recipients: A Single‐Center, Retrospective Analysis , 2004, Pharmacotherapy.

[23]  B. Alexander,et al.  Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  P. Changelian,et al.  The Novel JAK‐3 Inhibitor CP‐690550 Is a Potent Immunosuppressive Agent in Various Murine Models , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  S. Hossain,et al.  Cytomegalovirus Disease in High‐Risk Transplant Recipients Despite Ganciclovir or Valganciclovir Prophylaxis , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  D. McGiffin,et al.  Combination Prophylaxis with Ganciclovir and Cytomegalovirus (CMV) Immune Globulin After Lung Transplantation: Effective CMV Prevention Following Daclizumab Induction , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  C. Craddock,et al.  High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. , 2002, Blood.

[28]  S. Gautam,et al.  Prevention of cytomegalovirus infection and disease after lung transplantation: results using a unique regimen employing delayed ganciclovir. , 2002, Chest.

[29]  G. Raghu,et al.  High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. , 2002, The Journal of infectious diseases.

[30]  M. Zamora.  Use of cytomegalovirus immune globulin and ganciclovir for the prevention of cytomegalovirus disease in lung transplantation , 2001, Transplant infectious disease : an official journal of the Transplantation Society.

[31]  A. Husain,et al.  Quantification of cytomegalovirus (CMV) viral load by the hybrid capture assay allows for early detection of CMV disease in lung transplant recipients. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[32]  B. Alexander,et al.  Infectious complications of lung transplantation , 2001, Transplant infectious disease : an official journal of the Transplantation Society.

[33]  G. Raghu,et al.  Comparison of the efficacy and cost effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[34]  C. Couchoud.  Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation. , 1998, The Cochrane database of systematic reviews.

[35]  D. DuBois,et al.  Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation. , 1999, Chest.

[36]  L. Sharples,et al.  Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recipients , 1999, Transplant international : official journal of the European Society for Organ Transplantation.

[37]  R. Speich,et al.  Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation. , 1999, Transplantation.

[38]  R. Bolman,et al.  Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation. , 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[39]  M. Krajden,et al.  Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin. , 1998, Chest.

[40]  G. Berry,et al.  Risk factors for the development of obliterative bronchiolitis after lung transplantation. , 1996, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[41]  G. Berry,et al.  Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. , 1996, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[42]  B. Griffith,et al.  Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. , 1995, The Journal of thoracic and cardiovascular surgery.

[43]  B. Griffith,et al.  A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. , 1994, American journal of respiratory and critical care medicine.

[44]  J. Maurer,et al.  Outcomes of lung transplantation using three different cytomegalovirus prophylactic regimens. , 1993, Transplantation proceedings.

[45]  E. Spitznagel,et al.  Cytomegalovirus Infection and Pneumonitis: Impact after Isolated Lung Transplantation , 1993 .

[46]  B. Griffith,et al.  Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. , 1992, The American review of respiratory disease.

[47]  B. Griffith,et al.  Cytomegalovirus infection and survival in lung transplant recipients. , 1991, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.